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INTRODUCTION 58
The glucagon-like peptide-1 receptor (GLP1R) is a secretin family class B G protein-coupled 59 receptor (GPCR) characterized by hormone regulation. 1 Due to its involvement in glucose 60 homeostasis, the GLP1R has become a blockbuster target for the treatment of type 2 61 diabetes mellitus. 2 The endogenous ligand, glucagon-like peptide-1 (GLP-1) is released from 62 enteroendocrine L-cells in the gut in response to food intake, 3 from where it travels to the 63 pancreas before binding to its cognate receptor expressed in β-cells. Following activation, 64
the GLP1R engages a cascade of signaling pathways including Ca 2+ , cAMP, ERK and β-65
arrestin, which ultimately converge on β-cell survival and the glucose-dependent 66 amplification of insulin release. 4,5 GLP1R is also expressed in the brain 6 and muscle 7 where 67 it further contributes to metabolism via effects on food intake, energy expenditure, 68 locomotion and insulin sensitivity. Despite this, GLP1R localization remains a challenge and 69
is impeding functional characterization of GLP-1 and drug action. 70
Chemical biology and recombinant genetics have made available a diverse range of 71 methods for the visualization of biological entities. Thus, classical fluorescent protein-72
fusions, 8 self-labeling suicide enzymes (SNAP-, CLIP-, and Halo-tag), [9] [10] [11] "click 73 chemistry" 12,13 and fluorogenic probes [14] [15] [16] have provided unprecedented insight into the 74 localization and distribution of their respective targets in living cells. In particular, current 75 approaches for visualizing the GLP1R have so far relied on monoclonal antibodies (mAbs) 76 directed against GLP1R epitopes, 17,18 or fluorescent analogues of Exendin4(1-39), 19-21 a 77 stabilized form of GLP-1 and the basis for the incretin-mimetic class of drugs. Moreover, 78
floxed mouse models exist in which Cre recombinase is driven by the Glp1r promoter, 79
allowing labeling of GLP1R-expressing cells when crossed with reporter mice. 6,7 80
Such methods have a number of shortcomings. Antibodies possess variable specificity 18 and 81 tissue penetration, and GLP1R epitopes might be hidden or preferentially affected by fixation 82
in different cell types. Even more, fluorescent analogues of Exendin4(1-39) activate and 83
internalize the receptor, which could confound results in live cells, particularly when used as 84 a tool to sort purified populations (i.e. β-cells) for transcriptomic analysis. 22, 23 On the other 85 hand, reporter mouse strategies possess high fidelity, but cannot account for post-86 translational processing, protein stability and trafficking of native receptor. 24 Lastly, none of 87 the aforementioned approaches are amenable to super-resolution imaging of GLP1R. 88
Given the wider reported roles of GLP-1 signaling in the heart, 25 liver, 26 immune system 2 and 89 brain, 27 it is clear that new tools are urgently required to help identify GLP-1 target sites, with 90
repercussions for drug treatment and its side effects. In the present study, we therefore set 91 out to generate a specific probe for endogenous GLP1R detection in its native, surface-92 exposed state in live and fixed tissue, without receptor activation. Herein, we report 93
LUXendin645 and LUXendin651, Cy5-and SiR-conjugated far-red fluorescent antagonists 94 with unprecedented specificity, live tissue penetration and super-resolution capability. Using 95 our tools, we provide an updated view of GLP1R expression patterns in the islet of 96
Langerhans, show that endogenous GLP1Rs form nanodomains at the membrane and 97 reveal receptor subpopulations with distinct diffusion modes. Lastly, we find that installation 98 of a TMR fluorophore unexpectedly confers potent agonist properties. As such, the 99
LUXendins provide the first nanoscopic characterization of a class B GPCR, with wider 100 flexibility for detection and interrogation of GLP1R in the tissue setting. 101 As a first assessment of GLP1R labeling efficiency, we probed YFP-AD293-SNAP_GLP1R 133 cells with increasing concentrations of LUXendin645. Maximum labeling occurred at 100 nM 134 ( Fig. 2c ), in good agreement with the previously published K d = 15.8 nM of native 135
Exendin4(9-39) 31 . LUXendin645 was unable to label YFP-AD293 cells in which the GLP1R 136
was absent ( Fig. 2d ). 137
We next examined whether LUXendin645 would allow labeling of endogenous GLP1R.
138
Following 60 min application of 50 nM LUXendin645, isolated islets demonstrated intense 139 and clean labeling, which was restricted to the membrane ( Fig. 2e ). Using conventional 140 confocal microscopy, we were able to detect bright staining even 60 µm into the islet (Fig.  141 2e). Given these results, we next attempted to penetrate deeper into the islet by taking 142 advantage of the superior axial resolution of two-photon excitation ( Fig. 2f ). Remarkably, this 143
imaging modality revealed LUXendin645 labeling at high resolution throughout the entire 144 volume of the islet (170 µm in this case) ( Fig. 2f ). Consistent with the cAMP assays, 145
profound GLP1R internalization was detected following co-application of LUXendin645 and 146 BETP to MIN6 β-cells, which endogenously express the receptor (Fig. 2g, h) . 147
LUXendin645 allows multiplexed GLP1R detection 148
Demonstrating flexibility, LUXendin645 labeling was still present following formaldehyde 149 fixation ( Fig. 2i, j ). Immunostaining using a specific primary monoclonal antibody against the 150 GLP1R revealed strong co-localization with LUXendin645 in both islets ( Fig. 2i ) and MIN6 151 cells ( Fig. 2j ). Notably, LUXendin645 displayed superior signal-to-noise-ratio and membrane 152 resolution compared to the antibody (Fig. 2k ), expected to be even better in live tissue where 153 auto-fluorescence is less. Likewise, LUXendin645 co-localized with SNAP-Surface 488 in 154 SNAP_GLP1R-INS1 rat β-cells generated on an endogenous null background ( Fig. 2l ).
155
Suggesting that LUXendin645 requires the presence of surface GLP1R, labeling was 156 markedly reduced following prior internalization with Exendin4(1-39) ( Fig. 2l , m). 157
LUXendin645 specifically binds the GLP1R 158
To further validate the specificity of LUXendin645 labeling in primary tissue, we generated 159
Glp1r knock-out mice. This was achieved using CRISPR-Cas9 genome editing to introduce 160 a deletion into exon 1 of the Glp1r. The consequent frameshift was associated with absence 161 of translation and therefore a global GLP1R knockout, termed Glp1r (GE)-/-, in which all intronic 162 regions, and thus regulatory elements, are preserved ( Fig. 3a, b ). Wild-type (Glp1r +/+ ), 163
heterozygous and homozygous littermates were phenotypically normal and possessed 164 similar body weights ( Fig. 3c ). 165
Confirming successful GLP1R knock-out, insulin secretion assays in islets isolated from 166
Glp1r (GE)-/mice showed intact responses to glucose, but absence of Exendin4(1-39)-167 stimulated insulin secretion ( Fig. 3d ). Reflecting this finding, the incretin-mimetic Liraglutide 168
was only able to stimulate cAMP rises in islets from wild-type (Glp1r +/+ ) littermates, 169 measured using the FRET probe Epac2-camps ( Fig. 3e , f). As expected, immunostaining 170
with monoclonal antibody showed complete absence of GLP1R protein ( Fig. 3g ). Suggesting 171
that LUXendin645 specifically targets GLP1R, with little to no cross-talk from glucagon-172 receptors, 32 signal could not be detected in Glp1r (GE)-/islets ( Fig. 3g ). 173
Together, these data provide strong evidence for a specific mode of LUXendin645 action 174 via the GLP1R. 175
LUXendin645 highlights weak GLP1R expression 176
Previous approaches have shown low abundance of Glp1r transcripts in the other major islet 177 endocrine cell type, i.e. glucagon-secreting α-cells. 7,33 This is associated with detection of 178 GLP1R protein in ~1-10% of cells, 7,34 providing an excellent testbed for LUXendin645 179 sensitivity. Studies in intact islets showed that LUXendin645 labeling was widespread in the 180 islet and well co-localized with insulin immunostaining (Fig. 4a ). However, LUXendin645 181 could also be seen on membranes very closely associated with α-cells and somatostatin-182 secreting δ-cells ( Fig. 4b, c ), similarly to results obtained with GLP1R mAb. Due to the close 183 apposition of β-, αand δ-cell membranes, we were unable to accurately assign cell-type 184 specificity to LUXendin645. Instead, using cell clusters plated onto coverslips, we could 185 better discern LUXendin645 labeling, revealing GLP1R expression in 18 ± 6% of α-cells 186 ( Fig. 4d-f ), higher than that shown before using antibodies 19,34 and reporter genes 7 . Notably, 187
GLP1R-expressing α-cells tended to adjoin, whereas those without the receptor were next to 188 β-cells. Confirming previous findings, a majority (86 ± 3%) of β-cells were positive for 189
LUXendin645 (Fig 4d-f) . 7,19 190 We wondered whether fixation required for immunostaining might increase background 191 fluorescence such that GLP1R detection specificity was reduced. To circumvent this, studies 192
were repeated in live islets where LUXendin645 signal was found to be much brighter and 193
background almost non-existent. GLP1R was detected in 26.2 ± 1.1 % of non-β-cells ( Fig  194  4g , h) using Ins1Cre Thor ;R26 mTmG reporter mice in which β-cells are labeled green and all 195 other cell types are labeled red following Cre-mediated recombination. Once adjusted for the 196 previously reported GLP1R expression in δ-cells (assuming 100%), which constitute ~20% 197 of the insulin-negative islet population, 35 this leaves ~6% of GLP1R+ α-cells. This was not an 198 artefact of optical section, since two-photon islet reconstructions showed similar absence of 199
LUXendin645 staining in discrete regions near the surface (where α-cells predominate) 200
(Movie S1). 201
LUXendin645 and Luxendin651 reveal higher-order GLP1R organization 202
By combining LUXendin645 with Super-Resolution Radial Fluctuations (SRRF) analysis, 36 203 GLP1R could be imaged at super-resolution using streamed images (~ 1000) from a 204 conventional widefield microscope ( Fig. 5a ). To image endogenous GLP1R at < 100 nm 205 lateral resolution, we combined STED nanoscopy with LUXendin651, which bears silicon 206 rhodamine (SiR) instead of Cy5. LUXendin651 produced bright labeling of wild-type but not 207
Glp1r (GE)-/islets, with an identical distribution to LUXendin645 ( Supplementary Fig. S1 ).
208
Incubation of MIN6 cells with LUXendin651 and subsequent fixation allowed STED imaging 209 of the endogenous GLP1R with a FWHM = 70±10 nm ( Fig. 5b , c). STED snapshots of MIN6 210 β-cells revealed GLP1R distribution with unprecedented detail: receptors were not randomly 211 arranged but rather tended to organize into nanodomains with neighbors ( Fig. 5b , c). This 212 was confirmed using the F-and G-functions, which showed a non-random and more 213 clustered GLP1R distribution ( Fig. 5d , e). Differences in GLP1R expression level and pattern 214 could clearly be seen between neighboring cells with a subpopulation possessing highly 215 concentrated GLP1R clusters ( Fig. 5f ). 216
Finally, to test whether LUXendin645 and LUXendin651 would be capable of tracking 217
GLP1Rs in live cells, we performed single-molecule microscopy experiments in which 218
individual receptors labeled with either fluorescent probe were imaged by total internal 219 reflection fluorescence (TIRF) microscopy. 37,38 Both probes allowed GLP1R to be tracked at 220
the single-molecule level in CHO-K1-SNAP_GLP1R cells, but brightness and bleaching 221 precluded longer recordings with LUXendin645 ( Fig. 5g and Supplementary Movies S2, 222 S3). By combining single-particle tracking with LUXendin651, we were able to show that 223 most GLP1Rs diffuse rapidly at the membrane ( Fig. 5g and Supplementary Movie S4). 224
However, a mean square displacement (MSD) analysis 37 revealed a high heterogeneity in 225 the diffusion of GLP1Rs on the plasma membrane, ranging from virtually immobile receptors 226
to some displaying features of directed motion (superdiffusion) ( Fig. 5h ). 227
Altering fluorophore to produce LUXendin555 confers different ligand behavior 228
Lastly, we explored whether swapping the far-red Cy5/SiR for a TMR dye would be tolerated 229
to obtain a spectrally orthogonal probe, termed LUXendin555. Labeling was detected in 230 YFP-AD293-SNAP_GLP1R ( Fig. 6a ) but not YFP-AD293 cells ( Fig. 6b ). However, we 231 noticed a more punctate LUXendin555 staining pattern when viewed at high-resolutions 232 (Fig. 6c ). Further experiments with MIN6 cells and islets showed similar internalization of the 233 GLP1R ( Fig. 6d ), suggesting that LUXendin555 acts as an agonist, presumably via 234
interactions mediated by the ectodomain. This was confirmed using cAMP assays where 235
LUXendin555 was found to potently activate GLP1R signaling (EC 50 (cAMP) = 129.8 nM; 236 95% CI = 56.9-296.2) ( Fig. 6e ). Intriguingly, LUXendin555 potency could be further 237 increased using a PAM (EC 50 (cAMP) = 28.4 nM; 95% CI = 11.3-71.8) ( Fig. 6f ), suggesting a 238
unique binding conformation at the orthosteric site compared to agonists such as 239
Exendin4(1-39), which cannot be allosterically-modulated. 30 As for the other probes, 240
LUXendin555 was unable to label Glp1r (GE)-/islets ( Fig. S2) . 241
LUXendins label islets in vivo 242
We thought that the high quantum yield of TMR, coupled with good two-photon cross-section 243
and agonistic behaviour might suit LUXendin555 well to in vivo imaging where maintenance 244
of normoglycemia under anaesthesia can be an advantage for some experiments. Two-245 photon imaging was applied to an anaesthetized mouse to allow visualization of the intact 246 pancreas, exposed through an abdominal incision ( Fig. 6g ). Vessels and nuclei were first 247 labeled using FITC-dextran and Hoechst before injecting LUXendin555 intravenously. 248
Labeling occurred rapidly within 5 min post-injection, produced intense membrane staining 249
confined to the islet where GLP1R is expressed (Fig. 6h ), and normoglycemia was 250 maintained (250 mg/dl). No obvious internalization could be seen, most likely reflecting the 251 time of exposure to LUXendin555, as well as the concentration achieved in vivo at the islet. 252
DISCUSSION 253
In the present study, we synthesize and validate far-red fluorescent labels, termed 254
LUXendins for the real-time detection of GLP1R in live cells. Nanomolar concentrations of 255
LUXendin645 and LUXendin651 led to intense membrane-labeling of the GLP1R, with best 256 in class tissue penetration and signal-to-noise ratio, as well as super-resolution capability. 257
Notably, LUXendin645 and LUXendin651 did not activate the GLP1R unless agonist 258 activity is conferred with the widely-available PAM BETP. LUXendin645 and LUXendin651 259 are highly specific, as shown using a novel CRISPR-Cas9 mouse line lacking GLP1R 260 expression. Lastly, the analogous compound LUXendin555 bearing a different fluorophore 261
unusually displays agonistic activity, expanding the color palette and activity profile without 262
changing the peptidic pharmacophore. 263
Compared to present chemical biology approaches, LUXendins possess a number of 264 advantages for GLP1R labeling, which generally rely on Exendin4(1-39) labeled with for 265 instance Cy3, Cy5 or FITC. [19] [20] [21] 30 Firstly, the use of an antagonist encourages receptor 266
recycling back to the membrane and retains receptor at the cell surface, which likely 267 increases detection capability. Secondly, the GLP1R is not activated, meaning that results 268
can be interpreted in the absence of potentially confounding cell signaling, such as that 269 expected with agonists. 19 Thirdly, Cy5 occupies the far-red range, leading to less 270 background fluorescence, increasing depth penetration due to reduced scatter, and avoiding 271 the use of more phototoxic wavelengths. 39 To test the specificity of LUXendins, we used CRISPR-Cas9 genome-editing to globally 275 knock out the GLP1R in mice. Protein deletion was confirmed by absence of detectable 276 GLP1R signal following labeling with monoclonal antibody, LUXendin555, LUXendin645 277
and LUXendin651. While Glp1r -/animals already exist and have made important 278
contributions to our understanding of incretin biology, they were produced using a targeted 279 mutation to replace exons encoding transmembrane regions 1 and 3 (encoded by exons 5 280 and 7), presumably leading to deletion of the introns in between (~6.25 kb). 40 By contrast, 281
Glp1r (GE)-/mice possess intact introns. Since introns contain regulatory elements, such as 282 distant-acting enhancers 41 , miRNAs 42 and lncRNAs, 43 their loss in transgenic knockouts 283 could have wider influence on the transcriptome. GLP1R knock-out mice might therefore be 284 useful alongside conventional approaches for validating GLP1R reagents, including 285
antibodies, agonist and antagonist, and derivatives thereof. 286
Demonstrating the excellent sensitivity of the Cy5-linked LUXendin645 in particular, we 287
were able to detect GLP1R in ~6-18% of α-cells. Understanding α-cell GLP1R expression 288
patterns is important because incretin-mimetics reduce glucagon secretion, 44 which would 289 otherwise act to aggravate blood glucose levels. However, previous studies using 290
antibodies, reporter animals and agonist-fluorophores have shown ~1-10% GLP1R 291 expression in mouse and rat α-cells, in line with the low transcript abundance 7,19,33,45 , despite 292
reports that GLP-1 can directly suppress glucagon release. 34, 46 Our data are in general 293 concordance with these findings, but demonstrate an increase in detection capability for 294
native GLP1R. This improvement is likely related to the superior SNR of LUXendin645 295 compared to mAb and agonist-fluorophore, increasing the ability to resolve relatively low 296 GLP1R levels. A recent report showed GLP1R expression in ~80% of α-cells using a novel 297 antibody raised against the N-terminal region, with both membrane and cytosolic staining 298 evident 47 . While the reasons for this discrepancy are unknown, it should be noted that 299
LUXendin645 binds the orthosteric site and so reports the proportion of GLP1R that is 300 "signaling competent". 7, 19, 32 . 301
Since LUXendin645 showed excellent signal-to-noise ratio using conventional 302 epifluorescence, it was highly amenable to SRRF analysis. As such, LUXendin645 and its 303 congeners open up the possibility to image the GLP1R at super-resolution using simple 304 widefield microscopy available in most laboratories. For stimulated emission depletion 305
(STED) microscopy experiments, Cy5 was replaced with SiR to give LUXendin651. STED 306
imaging showed that endogenous GLP1R possess a higher structural order, namely 307 organization into nanodomains at the cell membrane. The presence of nanodomains under 308 non-stimulated conditions might reflect differences in palmitoylation, which has recently been 309
shown to influence GLP1R membrane distribution in response to agonists. 48 Notably, a 310 subpopulation of β-cells appeared to possess highly-concentrated GLP1R clusters. It will be 311 important in the future to investigate whether this is a cell autonomous heterogenous trait, or 312
instead reflects biased orientation of membranes toward specific β-cells. Lastly, both 313
LUXendin645 and LUXendin651 allowed GLP1Rs to be imaged in live cells by single-314 molecular microscopy, revealing variability in their diffusion at the plasma membrane. 315
Particle tracking analyses segregated GLP1R into four different populations based upon 316 diffusion mode, in keeping with data from beta adrenergic receptors. 37 Together, these 317 experiments provide the first super-resolution characterization of a class B GPCR and 318
suggest a degree of complexity not readily appreciated with previous approaches. 319
Intriguingly, we saw that swapping Cy5 for a TMR moiety to give LUXendin555 completely 320
changed the pharmacological behavior. The reasons for this are unknown, but we speculate 321 that the rhodamine scaffold engages a secondary binding site in the GLP1R ectodomain, 322
leading to activation. This finding is remarkable because it suggests that the agonist  323
antagonist switch that occurs following removal of eight N-terminal amino acids (as 324 physiologically mediated by the protease DPP-4) 49 can be counteracted simply by installing 325 a C-terminal linked rhodamine fluorophore, with implications for the design of more stable 326 GLP1R activators. More generally, this shift in compound behaviour following a fluorophore 327 modification serves as another instructive example for the thorough validation of all new 328 chemical labels. 50 Nonetheless, LUXendin555 possessed advantageous properties for in 329 vivo imaging including maintenance of relatively stable glycemia, good two-photon cross-330 section and high quantum yield. 331
In summary, we provide a comprehensively-tested and unique GLP1R detection toolbox 332
consisting of far-red antagonist labels, LUXendin645 and LUXendin651, an agonist 333
LUXendin555, and knockout Glp1r (GE)-/animals. Using these freely-available probes, we 334
provide an updated view of GLP1R organization, with relevance for the treatment of complex 335 metabolic diseases such as obesity and diabetes, as well as production of more stable 336 GLP1R activators. Thus, the stage is set for visualizing GLP1R in various tissues using a 337 range of imaging techniques, as well as the production of novel peptidic labels and agonists. 338
METHODS 340

Synthesis 341
Solid-phase peptide synthesis of S39C-Exendin4(9-39) was performed as previously 342
reported. 29 Maleimide-conjugated-6-TMR, -6-SiR and -Cy5 were obtained by TSTU 343 activation of the corresponding acids and reaction with 1-(2-amino-ethyl)-pyrrole-2,5-dione 344
(TFA salt, Aldrich). Fluorophore coupling via thiol-maleimide chemistry to peptides was 345 performed in PBS. All compounds were characterized by HRMS and purity was assessed to 346 be >95% by HPLC. human SNAP_GLP1R, before FACS of the SNAP-Surface488-positive population and 364 selection using G418. 48 The resulting SNAP_GLP1R_INS1 GLP1R-/cells were maintained in 365
RPMI-1640 supplemented with 10% FBS, 10 mM HEPES, 2 mM L-glutamine, 1 mM 366 pyruvate, 72 µM β-mercaptoethanol, 1% penicillin/streptomycin and 500 μg/mL G418. template were injected at 20 ng/µl into the pronucleus of embryos at the 1-cell stage. In 373 culture, 80% of embryos reached the 2-cell stage and were transplanted into surrogate mice. 374
The targeted locus of offspring was analyzed by PCR and sequencing. Besides the insertion 375 of the repair template, deletions of up to 27 nucleotides could be detected in 2 out of 6 376
offspring. Design of the repair template will be described elsewhere. Off-target sites were 377 predicted using the CRISPR Guide Design Tool (crispr.mit.edu). Loci of the top ten off-target 378 hits were amplified by PCR and analyzed via Sanger sequencing. Founder animals carrying 379 alleles with small deletions were backcrossed to wild type animals (strain C57BL/6J) for 1-2 380 generations to outbreed affected off-targets and then bred to homozygosity. Animals with the 381 larger deletion of 27 nucleotides were not taken forward, as GLP1R protein was still present. 382
Animals were born in Mendelian ratios and genotyping was performed using Sanger 383 sequencing. Animals were bred as heterozygous pairs to ensure Glp1r +/+ littermates. 384
Glp1r (GE)-/animals are freely available for academic use, subject to a Material Transfer 385
Agreement. 386
Ins1Cre Thor ;R26 mT/mG : To allow identification of βand non-β-cells, Ins1Cre Thor animals with 387
Cre knocked-in at the Ins1 locus (strain B6(Cg)-Ins1 tm1.1(cre)Thor /J) were crossed with R26 mT/mG 388 reporter mice (strain B6.129(Cg)-Gt(ROSA)26Sor tm4(ACTB-tdTomato,-EGFP)Luo /J). Cre-dependent 389 excision of the floxed allele results in deletion of tdTomato, expression of membrane-390 localized GFP and thus identification of recombined and non-recombined cells. 391
All studies were performed with 6-12 week old male and female animals, and regulated by 392
the Animals (Scientific Procedures) Act 1986 of the U.K. Approval was granted by the 393
University of Birmingham's Animal Welfare and Ethical Review Body. 394
Islet isolation 395
Islets were isolated from male and female Glp1r (GE)-/and Ins1Cre Thor ;R26 mT/mG mice, as well 396
as CD1 wild-type animals, maintained under specific-pathogen free conditions, with ad lib 397 access to food and water. Briefly, animals were humanely euthanized before injection of 398 collagenase 1 mg/mL (Serva NB8) into the bile duct. Following removal of the inflated 399 pancreas and digestion for 12 min at 37 °C, islets were separated using a Histopaque 400
(Sigma-Aldrich) gradient. Islets were cultured in RPMI medium containing 10% FCS, 100 401 units/mL penicillin, and 100 μg/mL streptomycin. 402
Binding and potency assays 403
Binding assays were performed in transiently-transfected YFP-AD293-SNAP_GLP1R cells 404 (using PolyJet reagent; SignaGen). Increasing concentrations of compound were applied for 405 60 min, before imaging using a Zeiss LSM880 meta-confocal microscope configured with 406
GaAsP detectors and 10×/0.45 W, 40x/1.00 W and 63×/1.20 W objectives. YFP, TMR 407 (LUXendin555) and Cy5 (LUXendin645) were excited using λ = 514 nm, λ = 561 nm and λ 408 = 633 nm lasers, respectively. Emitted signals were captured at λ = 519-574 nm, λ = 570-409 641 nm and λ = 638-759 nm for YFP, TMR (LUXendin555) and Cy5 (LUXendin645), 410
respectively. Control experiments were performed in YFP-AD293-SNAP cells, as above. 411
Potency for cAMP generation and inhibition was tested in heterologous expression systems, 412
comprising either stable CHO-K1-SNAP_GLP1R cells or transiently-transfected YFP-413
AD293-SNAP_GLP1R cells, as previously described. 29 Briefly, cells were incubated with 414 increasing concentrations of compound +/-allosteric modulator for 30 min, before 415
harvesting, lysis and measurement of cAMP using cAMP-Glo TM Assay (Promega), according 416
to the manufacturer's instructions. EC 50 values were calculated using log concentration-417 response curves fitted with a three-parameter equation. 418
Live imaging 419
Islets were incubated for 1 h at 37 °C in culture medium supplemented with either 100-250 420
nM LUXendin555, 50-100 nM LUXendin645 or 100 nM LUXendin651, based upon binding 421 assays. Islets were imaged using either a Zeiss LSM780 or LSM880 microscope, as above 422
(LUXendin651 was imaged as for LUXendin645). Ins1Cre Thor ;R26 mT/mG islets were excited 423 at λ = 488 nm (emission, λ = 493-555 nm) and λ = 561 nm (emission, λ = 570-624 nm) for 424 mGFP and tdTomato, respectively. Two-photon imaging of LUXendin645 was performed 425 using a Zeiss LSM 880 NLO equipped with a Spectra-Physics Insight X3 femtosecond-426 pulsed laser and 20x/1.00 W objective. Excitation was performed at λ = 800 nm and emitted 427 signals detected at λ = 638-759 nm. 428
cAMP imaging 429
Islets were transduced with adenovirus harboring the FRET sensor, Epac2-camps, before 430
imaging using a Crest X-Light spinning disk system coupled to a Nikon Ti-E base and 431 10x/0.4 NA objective. Excitation was delivered at λ = 430-450 nm using a Lumencor Spectra 432 X light engine. Emitted signals were detected at λ = 460-500 and λ = 520-550 nm for 433
Cerulean and Citrine, respectively, using a Photometrics Delta Evolve EM-CCD. Imaging 434 was performed in HEPES-bicarbonate buffer, containing (in mmol/L) 120 NaCl, 4.8 KCl, 24 435
NaHCO 3 , 0.5 Na 2 HPO 4 , 5 HEPES, 2.5 CaCl 2 , 1.2 MgCl 2 , and 3-17 D-glucose. Vehicle 436 (H 2 0), Exendin4(1-39) (10-20 nM) or Liraglutide (10 nM) were applied at the indicated time 437 points, with forskolin (10 µM) acting as a positive control. 438
Immunostaining 439
LUXendin555-or LUXendin645-treated cells or tissue were fixed for 60 min in 4% 440
paraformaldehyde. Primary antibodies were applied overnight at 4 °C in PBS + 0.1% Triton 441 + 1% BSA. Secondary antibodies were applied in the same buffer for 1 h at room 442 temperature, before mounting on slides using Vectashield Hardset containing DAPI. Primary 443 antibodies were mouse monoclonal anti-GLP1R 1:30 (Iowa DHSB; mAb #7F38), rabbit anti-444
insulin 1:500 (Cell Signaling Technology, #3014), mouse monoclonal anti-glucagon 1:2000 445
(Sigma-Aldrich, #G2654) and mouse anti-somatostatin 1:5000 (Invitrogen, #14-9751-80).
446
Secondary antibodies were goat anti-mouse Alexa Fluor 568 and donkey anti-rabbit DyLight 447 488 1:1000. Images were captured using an LSM880 meta-confocal microscope. Alexa 448
Fluor 488 and Alexa Fluor 568 were excited at λ = 488 nm and λ = 568 nm, respectively. 449
Emitted signals were detected at λ = 500-550 nm (Alexa Fluor 488) and λ = 519-574 nm 450
(Alexa Fluor 568). 451 objective lens. Following excitation at λ = 640 nm, fluorescence was acquired in the spectral 467 window λ = 650-800 nm. Deconvolution was performed with Richardson-Lucy algorithm on 468
Super-resolution microscopy
Imspector software. FWHM was measured on raw data and calculated using OriginPro 2017 469 software with Gaussian fitting (n=15 profiles). Spatial GLP1R expression patterns were 470 analyzed using the F-and G-functions, where F = distance between an object of interest and 471 its nearest neighbor, and G = distance from a given position to the nearest object of interest 472
(FIJI Spatial Statistic 2D/3D plugin). 52 Both measures were compared to a random 473 distribution of the same measured objects, with a shift away from the mean +/-95% 474 confidence intervals indicating a non-random or clustered organization (i.e. more space or 475 smaller distance between objects). 476
Single-molecule microscopy: For single-molecule experiments, CHO-K1-SNAP_GLP1R cells 477
were seeded onto 25 mm clean glass coverslips at a density of 3x 10 5 per well. On the 478 following day, cells were labeled in culture medium with 100 pM LUXendin645 or 479
LUXendin651 for 20 min. At the end of the incubation, cells were washed 3x 5 min in culture 480 medium. Cells were then imaged at 37 °C in phenol-red free Hank's balanced salt solution, 481
using a custom built total internal reflection fluorescence microscope (Cairn Research) 482
based on an Eclipse Ti2 (Nikon, Japan) equipped with an EMCCD camera (iXon Ultra, 483
Andor), 637 nm diode laser, and a 100x oil-immersion objective (NA 1.49, Nikon). Image 484 sequences were acquired with an exposure time of 60 ms. Single-molecule image 485
sequences were analyzed with an automated particle detection software (utrack) in the 486 MATLAB environment, as previously described. 53, 54 . Data were further analyzed using 487 custom MATLAB algorithms, as previously described. 37,55 488
Two-photon in vivo imaging 489
A 7 week old female C57BL/6J mouse was anesthetized with isoflurane and a small, 1 cm 490 vertical incision was made at the level of the pancreas. 
Statistical analyses 503
Measurements were performed on discrete samples unless otherwise stated. All analyses 504
were conducted using GraphPad Prism software. Unpaired or paired Students t-test was 505 used for pairwise comparisons. Multiple interactions were determined using one-way 506
ANOVA followed by Dunn's or Sidak's posthoc tests (accounting for degrees of freedom). 507
Data availability 508
The datasets generated during and/or analysed during the current study are available from 509 the corresponding author on reasonable request. 
